Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON L ALDRED

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1003969684
CMS profile
91043
Location
SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$149,319.46

136 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON L ALDRED

NPI 1003969684 · CMS profile ID 91043

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003969684?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON L ALDRED, NPI 1003969684, CMS profile ID 91043. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003969684?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JASON L ALDRED, NPI 1003969684, CMS profile ID 91043. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003969684?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JASON L ALDRED, NPI 1003969684, CMS profile ID 91043, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1003969684?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

136 matching records · $149,319.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 136 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 136.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $550.0008/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022577771 CMS
Teva Pharmaceuticals USA, Inc. $1,250.0008/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056746145 CMS
Boston Scientific Corporation $21.5608/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022212205 CMS
Teva Pharmaceuticals USA, Inc. $6.5408/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745951 CMS
Cala Health, Inc. $30.1208/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051477585 CMS
Amneal Pharmaceuticals LLC $27.1208/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053472713 CMS
Teva Pharmaceuticals USA, Inc. $10.0407/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745939 CMS
Teva Pharmaceuticals USA, Inc. $3,125.0007/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056746115 CMS
Ipsen Biopharmaceuticals, Inc $27.3507/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045444523 CMS
Teva Pharmaceuticals USA, Inc. $3,125.0007/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056746119 CMS
Medtronic, Inc. $18.9507/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018800587 CMS
Neurocrine Biosciences, Inc. $26.4507/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051958113 CMS
Teva Pharmaceuticals USA, Inc. $5.4307/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745929 CMS
AbbVie Inc. $24.1806/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996114435 CMS
Teva Pharmaceuticals USA, Inc. $7.5806/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745921 CMS
Boston Scientific Corporation $31.5806/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022212233 CMS
Teva Pharmaceuticals USA, Inc. $6.1106/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745925 CMS
Teva Pharmaceuticals USA, Inc. $3,125.0006/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056746107 CMS
Cala Health, Inc. $22.0306/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051477577 CMS
Teva Pharmaceuticals USA, Inc. $3.4906/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745919 CMS
AbbVie Inc. $1,275.0006/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996114433 CMS
Boston Scientific Corporation $550.0006/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022577769 CMS
Boston Scientific Corporation $1,100.0006/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022577775 CMS
Teva Pharmaceuticals USA, Inc. $2,500.0006/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745947 CMS
Teva Pharmaceuticals USA, Inc. $4,688.0006/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745967 CMS
Neurocrine Biosciences, Inc. $13.1205/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051958107 CMS
Boston Scientific Corporation $28.3105/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022577757 CMS
Teva Pharmaceuticals USA, Inc. $491.0005/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056746217 CMS
Teva Pharmaceuticals USA, Inc. $736.5005/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056746215 CMS
ACADIA Pharmaceuticals Inc $17.4605/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053112619 CMS
ACADIA Pharmaceuticals Inc $8.4405/22/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053112622 CMS
Teva Pharmaceuticals USA, Inc. $10.0505/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745903 CMS
Neurocrine Biosciences, Inc. $39.9405/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051958085 CMS
Teva Pharmaceuticals USA, Inc. $7.4705/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745881 CMS
Teva Pharmaceuticals USA, Inc. $1,250.0005/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745923 CMS
AbbVie Inc. $8,500.0005/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996114427 CMS
AbbVie Inc. $4,250.0005/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996114429 CMS
AbbVie Inc. $4,250.0005/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996114431 CMS
Amneal Pharmaceuticals LLC $26.6205/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053472709 CMS
Teva Pharmaceuticals USA, Inc. $736.5005/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056746213 CMS
ACADIA Pharmaceuticals Inc $23.6305/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053112611 CMS
ACADIA Pharmaceuticals Inc $8.3505/03/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053112615 CMS
Boston Scientific Corporation $25.7005/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022577755 CMS
AbbVie Inc. $6,800.0005/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996114425 CMS
Medtronic, Inc. $24.4805/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018800571 CMS
Teva Pharmaceuticals USA, Inc. $8.0604/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056745883 CMS
AbbVie Inc. $133.9004/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996114415 CMS
AbbVie Inc. $270.4304/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996114417 CMS
AbbVie Inc. $160.0004/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996114419 CMS
AbbVie Inc. $27.1204/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996114421 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $150,720.33 195
PY2020 $82,516.03 104
PY2021 $130,067.67 109
PY2022 $87,658.19 101
PY2023 $149,319.46 136
PY2024 $202,809.07 226
PY2025 $211,648.42 218

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $835,478.58 153
PY2024 Principal investigator $1,046,326.69 152
PY2023 Principal investigator $787,126.66 113
PY2022 Recipient $26,338.23 5
PY2022 Principal investigator $1,112,168.40 108
PY2021 Recipient $2,041.31 3
PY2021 Principal investigator $2,663,850.01 134
PY2020 Recipient $10,150.00 2
PY2020 Principal investigator $1,035,471.93 153
PY2019 Recipient $34,054.40 5
PY2019 Principal investigator $1,019,571.77 96

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

153 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson s disease No dispute reported 06/30/2026 1202532677
Principal investigator 1 ABBVIE INC. $1,056.72 12/31/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson s Disease No dispute reported 06/30/2026 1202532839
Principal investigator 1 H. Lundbeck A S $6,291.85 12/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778635
Principal investigator 1 ABBVIE INC. $1,754.68 12/16/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202530612
Principal investigator 1 H. Lundbeck A S $2,404.45 12/11/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778293
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,936.80 12/11/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045254
Principal investigator 1 ABBVIE INC. $4,950.00 12/05/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202529368
Principal investigator 1 ABBVIE INC. $4,950.00 12/05/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinsons Disease No dispute reported 06/30/2026 1202529408
Principal investigator 1 ABBVIE INC. $10,091.25 12/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202527838
Principal investigator 1 ABBVIE INC. $406.90 12/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202528040
Principal investigator 1 H. Lundbeck A S $11,010.50 12/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778048
Principal investigator 1 ABBVIE INC. $3,116.08 12/01/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202526202
Principal investigator 1 Boston Scientific Corporation $910.00 11/25/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
US DBS REGISTRY No dispute reported 06/30/2026 1207575903
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,615.95 11/25/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy No dispute reported 06/30/2026 1244045258
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,292.55 11/20/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045252
Principal investigator 1 H. Lundbeck A S $16,722.85 11/14/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251777193
Principal investigator 1 H. Lundbeck A S $6,720.00 11/14/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251777197
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,615.95 11/14/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy No dispute reported 06/30/2026 1244045256
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $571.28 11/07/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045248
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,136.00 11/07/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045250
Principal investigator 1 ABBVIE INC. $15,552.00 11/05/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202521493
Principal investigator 1 H. Lundbeck A S $4,808.90 10/23/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251776002
Principal investigator 1 H. Lundbeck A S $1,024.50 10/23/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251776005
Principal investigator 1 H. Lundbeck A S $2,628.11 10/23/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251776009
Principal investigator 1 ABBVIE INC. $4,796.79 10/22/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202518123
Principal investigator 1 Genentech, Inc. $270.09 10/22/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211614721
Principal investigator 1 Genentech, Inc. $181.19 10/21/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614726
Principal investigator 1 ABBVIE INC. $600.00 10/16/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinsons Disease No dispute reported 06/30/2026 1202517075
Principal investigator 1 ABBVIE INC. $600.00 10/16/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202517269
Principal investigator 1 ABBVIE INC. $1,522.14 10/09/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202515429
Principal investigator 1 ABBVIE INC. $21,100.50 10/09/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202515647
Principal investigator 1 ABBVIE INC. $3,110.90 10/09/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202515649
Principal investigator 1 H. Lundbeck A S $7,326.40 10/09/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251775513
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,292.55 10/09/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045414
Principal investigator 1 H. Lundbeck A S $15,176.25 10/03/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251775211
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,936.80 10/03/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045412
Principal investigator 1 ABBVIE INC. $967.20 09/25/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202512190
Principal investigator 1 ABBVIE INC. $1,289.60 09/25/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202512310
Principal investigator 1 Boston Scientific Corporation $1,371.50 09/23/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
US DBS REGISTRY No dispute reported 06/30/2026 1207575901
Principal investigator 1 H. Lundbeck A S $15,149.65 09/23/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774962
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,482.95 09/23/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045410
Principal investigator 1 Genentech, Inc. $288.86 09/12/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614714
Principal investigator 1 H. Lundbeck A S $300.00 09/12/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774657
Principal investigator 1 H. Lundbeck A S $1,173.15 09/12/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774661
Principal investigator 1 H. Lundbeck A S $93.33 09/12/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774665
Principal investigator 1 H. Lundbeck A S $170.89 09/12/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774669
Principal investigator 1 H. Lundbeck A S $220.59 09/12/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774673
Principal investigator 1 H. Lundbeck A S $488.94 09/12/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774676
Principal investigator 1 Medtronic, Inc. $5,540.00 09/12/2025 Non-covered Recipient Entity
Arete Neuroscience Pllc
ADAPT-PD Trial No dispute reported 06/30/2026 1192331157
Principal investigator 1 ABBVIE INC. $3,110.90 09/11/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202510678
Principal investigator 1 ABBVIE INC. $1,379.00 09/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202508458
Principal investigator 1 ABBVIE INC. $170.75 09/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202509214
Principal investigator 1 H. Lundbeck A S $15,149.65 09/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774248
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,936.80 09/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045408
Principal investigator 1 Genentech, Inc. $354.00 08/27/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211614710
Principal investigator 1 H. Lundbeck A S $2,314.20 08/26/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251773941
Principal investigator 1 H. Lundbeck A S $2,400.00 08/26/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251773961
Principal investigator 1 H. Lundbeck A S $488.94 08/26/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251773964
Principal investigator 1 H. Lundbeck A S $20,160.00 08/26/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251773967
Principal investigator 1 H. Lundbeck A S $5,556.06 08/26/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251773972
Principal investigator 1 H. Lundbeck A S $13,440.00 08/21/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251773762
Principal investigator 1 Genentech, Inc. $424.99 08/11/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614718
Principal investigator 1 ABBVIE INC. $10,409.76 08/06/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202502646
Principal investigator 1 ABBVIE INC. $11,184.75 08/06/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202502648
Principal investigator 1 ABBVIE INC. $182.00 08/06/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202503607
Principal investigator 1 ABBVIE INC. $4,640.96 07/31/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202500740
Principal investigator 1 H. Lundbeck A S $3,977.65 07/31/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772874
Principal investigator 1 H. Lundbeck A S $300.00 07/31/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772906
Principal investigator 1 H. Lundbeck A S $1,450.00 07/31/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772909
Principal investigator 1 H. Lundbeck A S $1,800.00 07/31/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772913
Principal investigator 1 H. Lundbeck A S $8,800.00 07/31/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772918
Principal investigator 1 H. Lundbeck A S $93.33 07/31/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772922
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,419.75 07/31/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045406
Principal investigator 1 Boston Scientific Corporation $2,405.00 07/22/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
US DBS REGISTRY No dispute reported 06/30/2026 1207575899
Principal investigator 1 H. Lundbeck A S $6,382.10 07/22/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772744
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,272.00 07/22/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045396
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $162.98 07/22/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045398
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $58.93 07/22/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045400
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,347.66 07/22/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045402
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $750.00 07/22/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045404
Principal investigator 1 H. Lundbeck A S $4,245.86 07/17/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772397
Principal investigator 1 ABBVIE INC. $1,309.92 07/10/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202497884
Principal investigator 1 Genentech, Inc. $4,371.03 07/09/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614706
Principal investigator 1 ABBVIE INC. $9,025.00 07/08/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202497172
Principal investigator 1 ABBVIE INC. $16,773.75 07/08/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202497174
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $774.15 07/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045392
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,682.66 07/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045394
Principal investigator 1 Genentech, Inc. $1,267.16 07/01/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211614663
Principal investigator 1 Genentech, Inc. $343.00 06/25/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211614666
Principal investigator 1 H. Lundbeck A S $9,554.15 06/24/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251771512
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,342.45 06/19/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045390
Principal investigator 1 Genentech, Inc. $219.21 06/16/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211614655
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,936.80 06/12/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045388
Principal investigator 1 ABBVIE INC. $873.28 06/05/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202490425
Principal investigator 1 H. Lundbeck A S $15,239.90 06/05/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770743
Principal investigator 1 ABBVIE INC. $5,548.50 06/03/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202488485
Principal investigator 1 Genentech, Inc. $11,830.00 06/02/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211614658
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $889.00 06/01/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045386
Principal investigator 1 Genentech, Inc. $3,328.00 05/16/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614696
Principal investigator 1 H. Lundbeck A S $10,431.00 05/15/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770319
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,825.40 05/15/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045384
Principal investigator 1 H. Lundbeck A S $10,431.00 05/08/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770122
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,902.70 05/08/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045382
Principal investigator 1 ABBVIE INC. $4,110.75 05/07/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202482489
Principal investigator 1 ABBVIE INC. $6,682.50 05/07/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202482493
Principal investigator 1 Genentech, Inc. $39.33 05/06/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614682
Principal investigator 1 Genentech, Inc. $22,974.00 04/29/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211614688
Principal investigator 1 Sage Therapeutics, LLC $13,273.31 04/28/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) No dispute reported 06/30/2026 1206580813
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,552.70 04/28/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045380
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $27,442.31 04/23/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223278608
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,482.95 04/23/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045378
Principal investigator 1 H. Lundbeck A S $2,404.45 04/15/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251769680
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,976.61 04/15/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045374
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.46 04/15/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045376
Principal investigator 1 Genentech, Inc. $47.41 04/14/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614684
Principal investigator 1 Genentech, Inc. $15,217.00 04/10/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614692
Principal investigator 1 ABBVIE INC. $1,737.88 04/09/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202475114
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,770.45 04/09/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223277790
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.28 04/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223277592
Principal investigator 1 ABBVIE INC. $43,225.00 04/03/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202470139
Principal investigator 1 ABBVIE INC. $530.21 04/03/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202470557
Principal investigator 1 Boston Scientific Corporation $4,010.50 03/25/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
US DBS REGISTRY No dispute reported 06/30/2026 1207575897
Principal investigator 1 Sage Therapeutics, LLC $23,847.71 03/24/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease No dispute reported 06/30/2026 1206580809
Principal investigator 1 H. Lundbeck A S $10,431.00 03/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251768889
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,342.45 03/19/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045372
Principal investigator 1 Genentech, Inc. $45.52 03/12/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614701
Principal investigator 1 ABBVIE INC. $2,471.28 03/06/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
M15-737 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202456958
Principal investigator 1 ABBVIE INC. $3,110.90 03/06/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
M15-737 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202458659
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $32,930.80 03/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045370
Principal investigator 1 Boston Scientific Corporation $1,495.00 02/25/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
US DBS REGISTRY No dispute reported 06/30/2026 1207575895
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,725.00 02/13/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045364
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,200.00 02/13/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045366
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $116.78 02/13/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045368
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $52.98 02/12/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223275205
Principal investigator 1 Sage Therapeutics, LLC $21,003.44 02/06/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Study to Evaluate SAGE-324 in Participants With Essential Tremors No dispute reported 06/30/2026 1206580376
Principal investigator 1 ABBVIE INC. $2,851.99 02/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
M15-737 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202443811
Principal investigator 1 Genentech, Inc. $43.80 02/04/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614670
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,552.70 01/29/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244045362
Principal investigator 1 Boston Scientific Corporation $1,794.00 01/28/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
US DBS REGISTRY No dispute reported 06/30/2026 1207575889
Principal investigator 1 Boston Scientific Corporation $966.50 01/28/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
US DBS REGISTRY No dispute reported 06/30/2026 1207575891
Principal investigator 1 Boston Scientific Corporation $1,531.00 01/28/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
US DBS REGISTRY No dispute reported 06/30/2026 1207575893
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $65.89 01/17/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223274237
Principal investigator 1 Sage Therapeutics, LLC $13,416.47 01/16/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor No dispute reported 06/30/2026 1206580522
Principal investigator 1 Genentech, Inc. $12,628.00 01/15/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211614674
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $65.16 01/15/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223273939
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $66.55 01/15/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223273941
Principal investigator 1 ABBVIE INC. $9,025.00 01/14/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinsons Disease No dispute reported 06/30/2026 1202438190
Principal investigator 1 Genentech, Inc. $29.56 01/08/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211614677
Principal investigator 1 ABBVIE INC. $2,400.58 01/07/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
M15-737 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202437010
Principal investigator 1 ABBVIE INC. $2,400.58 01/07/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
M15-737 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202437014
Principal investigator 1 UCB SA $12,445.17 01/07/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658750
Principal investigator 1 ABBVIE INC. $3,086.10 01/02/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202435244
Principal investigator 1 ABBVIE INC. $406.90 01/02/2025 Non-covered Recipient Entity
INLAND NORTHWEST RESEARCH LLC
M15-737 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202435248